PR Newswire TechnologyCodex · 实盘不做把握 7/10
北京时间·🕒 发布 20:00:00时区推断·⟳ 抓取 20:01:13·⚡ 决策 07-27 20:01:57 +44s·92.2 天前
英矽智能ISM6331一期临床数据获ESMO 2026快速口头报告接收
本次只是一期临床研究数据被ESMO 2026接收为口头报告，尚未披露疗效、安全性或商业化数据。
📄 原文PR Newswire Technology↗ 原文
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Ad…
不做 英矽智能（03696.HK）
会议接收公告属于未来数据披露前的程序性里程碑，未给出疗效、安全性、入组或商业化量级，当前没有可回测的正期望入场边界，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 low · price-in 风险 medium ↗
关键理由
- 本次只是一期临床研究数据被ESMO 2026接收为口头报告，尚未披露疗效、安全性或商业化数据。
- ISM6331仍处于早期临床阶段，事件距离2026年10月正式报告仍有约三个月，短线无法量化收入、利润或估值重定价幅度。
- 公司PR属于里程碑宣传性质，缺少足以支持开仓的新增硬数据。
主要风险
- 若10月正式披露的客观缓解率、安全性或剂量扩展数据显著超预期，届时需要重新研判。
- 早期肿瘤药物临床数据不确定性高，单纯会议接收不等同于临床成功。
原文全文
展开原文 · 4,907 字
Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
News provided by
Insilico Medicine
Jul 27, 2026, 08:00 ET
Share this article
Share to
X
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway
Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors
CAMBRIDGE, Mass.
,
July 27, 2026
/PRNewswire/ -- Insilico Medicine ("Insilico", HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, today announced that first-in-human Phase 1 trial data for ISM6331, its novel AI-designed pan-TEAD inhibitor, has been accepted for a
Rapid Oral presentation
at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
"TEAD has long been recognized as an attractive target in hard-to-treat solid tumors, but small-molecule inhibition has historically posed significant design challenges,
said
Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine.
"The selection of ISM6331 for a Rapid Oral presentation at ESMO 2026 highlights the potential of our AI-generated platform to target complex oncogenic drivers like the Hippo pathway and represents a promising pan-TEAD approach that we are eager to share with the community."
Details of the Rapid Oral Presentation
Title:
First-in-human Multicenter Phase 1 Study of ISM6331, an AI-Designed Pan-TEAD Inhibitor, in Patients with Mesothelioma or Other Advanced Solid Tumors
Abstract Number:
#997
Session Name:
Rapid Oral Presentation: Developmental Therapeutic
Location:
Cordoba Auditorium - Hall 4
Date/Time:
Sunday 25.10.2026 08:30 - 10:00
"Presenting our first-in-human Phase 1 study at ESMO marks an important clinical milestone for ISM6331,"
Halle Zhang, Ph.D., Vice President, Clinical Development – Oncology at Insilico Medicine.
"Patients with advanced mesothelioma and other Hippo-driven solid tumors face limited therapeutic options. These preliminary clinical findings provide early encouragement as we evaluate ISM6331's safety, pharmacokinetics, and initial antitumor activity to inform our ongoing clinical development strategies."
About ISM6331
ISM6331 is a novel, potent, small-molecule pan-TEAD inhibitor discovered and designed using Insilico Medicine's proprietary generative AI-powered drug discovery platform, Chemistry42. The molecule targets TEAD transcription factors, the principal downstream effectors of the Hippo signaling pathway, a critical regulator of cell proliferation, survival, tissue homeostasis, and therapeutic resistance across a broad range of solid tumors. Although the Hippo pathway has long been recognized as a promising therapeutic target in oncology, developing effective small-molecule TEAD inhibitors has remained a significant medicinal chemistry challenge. ISM6331 was designed to selectively inhibit pan-TEAD activity and is being evaluated in a global, multicenter Phase 1 clinical trial in patients with malignant mesothelioma and other advanced solid tumors. The study is assessing ISM6331 safety, tolerability, pharmacokinetics, and preliminary antitumor activity to inform its continued clinical development.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-driven biotechnology company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for target discovery, small molecule generation, and clinical trial outcome prediction. Insilico Medicine develops breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
For more information, please visit
www.insilico.com
.
SOURCE Insilico Medicine
21
%
more press release views with
Request a Demo
×
Modal title
Also from this source
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
Despite the widespread availability of analgesics, pain management remains one of the most significant and pervasive challenges in modern medicine,...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a ...
More Releases From This Source
Explore
Biotechnology
Pharmaceuticals
Medical Pharmaceuticals
Health Care & Hospitals
News Releases in Similar Topics
News provided by
Insilico Medicine
Jul 27, 2026, 08:00 ET
Share this article
Share to
X
Presentation to feature first-in-human results for ISM6331, a novel, AI-designed pan-TEAD inhibitor targeting the Hippo pathway
Global Phase 1 multicenter study evaluates safety, tolerability, and preliminary efficacy in patients with mesothelioma and other advanced solid tumors
CAMBRIDGE, Mass.
,
July 27, 2026
/PRNewswire/ -- Insilico Medicine ("Insilico", HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, today announced that first-in-human Phase 1 trial data for ISM6331, its novel AI-designed pan-TEAD inhibitor, has been accepted for a
Rapid Oral presentation
at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
"TEAD has long been recognized as an attractive target in hard-to-treat solid tumors, but small-molecule inhibition has historically posed significant design challenges,
said
Feng Ren, Ph.D., Co-CEO and Chief Scientific Officer of Insilico Medicine.
"The selection of ISM6331 for a Rapid Oral presentation at ESMO 2026 highlights the potential of our AI-generated platform to target complex oncogenic drivers like the Hippo pathway and represents a promising pan-TEAD approach that we are eager to share with the community."
Details of the Rapid Oral Presentation
Title:
First-in-human Multicenter Phase 1 Study of ISM6331, an AI-Designed Pan-TEAD Inhibitor, in Patients with Mesothelioma or Other Advanced Solid Tumors
Abstract Number:
#997
Session Name:
Rapid Oral Presentation: Developmental Therapeutic
Location:
Cordoba Auditorium - Hall 4
Date/Time:
Sunday 25.10.2026 08:30 - 10:00
"Presenting our first-in-human Phase 1 study at ESMO marks an important clinical milestone for ISM6331,"
Halle Zhang, Ph.D., Vice President, Clinical Development – Oncology at Insilico Medicine.
"Patients with advanced mesothelioma and other Hippo-driven solid tumors face limited therapeutic options. These preliminary clinical findings provide early encouragement as we evaluate ISM6331's safety, pharmacokinetics, and initial antitumor activity to inform our ongoing clinical development strategies."
About ISM6331
ISM6331 is a novel, potent, small-molecule pan-TEAD inhibitor discovered and designed using Insilico Medicine's proprietary generative AI-powered drug discovery platform, Chemistry42. The molecule targets TEAD transcription factors, the principal downstream effectors of the Hippo signaling pathway, a critical regulator of cell proliferation, survival, tissue homeostasis, and therapeutic resistance across a broad range of solid tumors. Although the Hippo pathway has long been recognized as a promising therapeutic target in oncology, developing effective small-molecule TEAD inhibitors has remained a significant medicinal chemistry challenge. ISM6331 was designed to selectively inhibit pan-TEAD activity and is being evaluated in a global, multicenter Phase 1 clinical trial in patients with malignant mesothelioma and other advanced solid tumors. The study is assessing ISM6331 safety, tolerability, pharmacokinetics, and preliminary antitumor activity to inform its continued clinical development.
About Insilico Medicine
Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (AI)-driven biotechnology company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for target discovery, small molecule generation, and clinical trial outcome prediction. Insilico Medicine develops breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
For more information, please visit
www.insilico.com
.
SOURCE Insilico Medicine
21
%
more press release views with
Request a Demo
×
Modal title
Also from this source
Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management
Despite the widespread availability of analgesics, pain management remains one of the most significant and pervasive challenges in modern medicine,...
Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development
Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a ...
More Releases From This Source
Explore
Biotechnology
Pharmaceuticals
Medical Pharmaceuticals
Health Care & Hospitals
News Releases in Similar Topics
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。